A Study to Assess Deucravacitinib Safety in Pregnancy
← catalyst calendarNCT07017699 · readout in 590 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
900estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-21 | actual | When the study began enrolling |
| Primary completion | 2028-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriasis (PsO)
Interventions
- Drug: Deucravacitinib
- Drug: Other systemic treatments for PsO
Primary outcome
what the primary-completion date above is the date OFNumber of major congenital malformations among infants
measured 1-year post pregnancy outcome
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed